No connection

Search Results

MLSS

BEARISH
$0.31 Live
Milestone Scientific Inc. · AMEX
Target $1.0 (+222.6%)
$0.22 52W Range $1.11
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 30, 2026
Market cap
$27.41M
P/E
N/A
ROE
-132.4%
Profit margin
-63.8%
Debt/Equity
0.36
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
MLSS exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from chronic unprofitability with a profit margin of -63.77% and an ROE of -132.38%, while revenue growth has stagnated at a negligible 2.20% YoY. Despite a low debt-to-equity ratio, the poor quick ratio (0.44) and consistent earnings misses over 25 quarters suggest a failing business model. The stock is technically bearish with a 5-year price decline of 87.7%, making it a high-risk speculative asset with no fundamental floor.

Key Strengths

Strong gross margin of 71.40% suggesting a viable product core
Low Debt/Equity ratio (0.36) indicating minimal long-term leverage
Current ratio of 1.81 provides a temporary liquidity buffer
Analyst target price ($1.00) suggests significant theoretical upside
Operates in the resilient Healthcare sector

Key Risks

Critical financial health (Piotroski F-Score 1/9)
Chronic net losses with negative profit and operating margins
Stagnant revenue growth (2.20%) failing to scale the business
Poor liquidity indicated by a Quick Ratio of 0.44
Severe long-term value destruction (-87.7% over 5 years)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
13
Weak
Value
20
Future
25
Past
10
Health
10
Dividend
0
AI Verdict
Distressed Asset
Key drivers: Piotroski F-Score 1/9, Chronic negative earnings, Stagnant growth, Extreme price depreciation
Confidence
90%
Value
20/100

Ref P/E N/A, P/B 8.86

Positives
  • Low absolute share price
Watchpoints
  • Price/Book of 8.86 is excessive for a non-profitable company
  • No Graham Number available due to lack of earnings
Future
25/100

Ref Revenue Growth 2.20%

Positives
  • Positive (though minimal) revenue growth
Watchpoints
  • Revenue growth (2.2%) is far below sector average
  • Consistent earnings misses
Past
10/100

Ref Historical Price Performance

Positives
No standout positives identified.
Watchpoints
  • 5-year return of -87.7%
  • 1-year return of -67.4%
Health
10/100

Ref Piotroski F-Score

Positives
  • Low Debt/Equity
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROE and ROA
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • No capacity to pay dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.31
Analyst Target
$1.0
Upside/Downside
+222.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MLSS and closest competitors.

Updated 2026-04-29
MLS
Milestone Scientific Inc.
Primary
5Y
-87.7%
3Y
-58.1%
1Y
-67.4%
6M
-27.9%
1M
+3.3%
1W
-8.8%
AYT
Aytu BioPharma, Inc.
Peer
5Y
-98.4%
3Y
-24.2%
1Y
+61.7%
6M
+2.7%
1M
+6.7%
1W
+1.5%
TEL
TELA Bio, Inc.
Peer
5Y
-95.4%
3Y
-93.3%
1Y
-29.1%
6M
-57.4%
1M
-18.9%
1W
+12.7%
ICC
IceCure Medical Ltd
Peer
5Y
-97.0%
3Y
-71.2%
1Y
-71.9%
6M
-62.9%
1M
-51.7%
1W
+7.7%
KYN
Kyntra Bio, Inc.
Peer
5Y
-98.6%
3Y
-98.5%
1Y
+10.3%
6M
-32.0%
1M
+0.7%
1W
+2.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-7.75
PEG Ratio
N/A
P/B Ratio
8.86
P/S Ratio
3.05
EV/Revenue
2.77
EV/EBITDA
-4.42
Market Cap
$27.41M

Profitability

Profit margins and return metrics

Profit Margin -63.77%
Operating Margin -52.46%
Gross Margin 71.4%
ROE -132.38%
ROA -40.45%

Growth

Revenue and earnings growth rates

Revenue Growth +2.2%
Earnings Growth N/A
Q/Q Revenue Growth +2.21%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.36
Low debt
Current Ratio
1.81
Good
Quick Ratio
0.44
Poor
Cash/Share
$0.01

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
73.0%
Op. Margin
-52.5%
Net Margin
-53.0%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.78x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14
$N/A
2026-03-31
$-0.01
+33.3% surprise
2025-11-13
$-0.01
2025-08-14
$-0.02
-100.0% surprise

Healthcare Sector Comparison

Comparing MLSS against 571 companies in the Healthcare sector (37 bullish, 174 neutral, 360 bearish)
Return on Equity (ROE)
-132.38%
This Stock
vs
-86.81%
Sector Avg
+52.5% (Excellent)
Profit Margin
-63.77%
This Stock
vs
-16.0%
Sector Avg
+298.6% (Superior)
Debt to Equity
0.36
This Stock
vs
2.62
Sector Avg
-86.2% (Less Debt)
Revenue Growth
2.2%
This Stock
vs
121.82%
Sector Avg
-98.2% (Slower)
Current Ratio
1.81
This Stock
vs
4.44
Sector Avg
-59.2% (Weaker)

Similar Companies

Peer comparison within the same industry

MLSS Milestone Scientific Inc.
BEARISH
Mkt Cap
$27M
P/E
-
ROE
-132.4%
Price
$0.31
AYTU Aytu BioPharma, Inc.
NEUTRAL
Mkt Cap
$28M
P/E
-
ROE
-50.2%
Price
$2.7
 Compare with MLSS
TELA TELA Bio, Inc.
BEARISH
Mkt Cap
$28M
P/E
-
ROE
-223.4%
Price
$0.63
 Compare with MLSS
ICCM IceCure Medical Ltd
BEARISH
Mkt Cap
$26M
P/E
-
ROE
-188.8%
Price
$0.32
 Compare with MLSS
KYNB Kyntra Bio, Inc.
BEARISH
Mkt Cap
$29M
P/E
-
ROE
-%
Price
$7.17
 Compare with MLSS

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-21

MLSS filed an 8-K on April 21, 2026, likely to announce its quarterly financial results.

8-K
8-K
2026-04-02

MLSS filed a current report on April 2, 2026, likely announcing its annual financial results or the filing of its annual report.

10-K
10-K
2026-03-31

MLSS filed its annual 10-K report on March 31, 2026. The provided excerpts do not contain specific financial data or detailed risk factors, as only section headers and page numbers were included.

8-K
8-K
2026-03-11

MLSS filed an 8-K on March 11, 2026, likely to announce its annual financial results.

8-K/A
8-K/A
2026-02-04

MLSS filed an amendment to a previously submitted Current Report on February 4, 2026.

8-K
8-K
2026-01-20

MLSS filed an 8-K on January 20, 2026, likely to report year-end financial results or a material corporate event.

8-K
8-K
2025-12-23
8-K
8-K
2025-11-13

MLSS filed an 8-K on November 13, 2025, likely to announce its third-quarter financial results.

10-Q
10-Q
2025-11-13

MLSS filed its 10-Q on November 13, 2025, which includes disclosures regarding risk factors, unresolved staff comments, and cybersecurity. Due to the limited content provided, specific financial highlights and detailed risk exposures are not available.

DEF 14A
DEF 14A
2025-11-12

MLSS filed a Definitive Proxy Statement on November 12, 2025, providing shareholders with necessary information to vote on matters at an upcoming meeting.

8-K
8-K
2025-10-14
10-Q
FORM 10-Q
2025-08-14
8-K
FORM 8-K
2025-08-05
8-K
FORM 8-K
2025-05-19
10-Q
FORM 10-Q
2025-05-15
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
2 analysts
Benchmark
2025-11-20
Maintains
Speculative Buy Speculative Buy

Past News Coverage

Recent headlines mentioning MLSS from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile